<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148993</url>
  </required_header>
  <id_info>
    <org_study_id>100798-HMO-CTIL</org_study_id>
    <nct_id>NCT00148993</nct_id>
  </id_info>
  <brief_title>Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors</brief_title>
  <official_title>Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The International Center for Cell Therapy &amp; Cancer Immunotherapy (CTCI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in
      patients with micro-metastatic disease and/or in patients at high risk disease progression.
      The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC
      determinants with the patient aiming to overcome possible restriction of antigen
      presentation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI (Prof. Slavin) not longer work at Hadassah
  </why_stopped>
  <start_date>July 1998</start_date>
  <completion_date type="Anticipated">July 2005</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate the feasibility of immune responses against cancer cells by combining allogeneic TCV with indomethacin, cimetidine, tetanus and rIL-2.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metastatic Solid Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor Cell Vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with measurable metastatic disease or disease resistant to chemotherapy or
             with minimal residual disease at high risk to relapse.

        Exclusion Criteria:

          -  Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic agents
             or immunosuppressive agents which may interfere with optimal immune response.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shimon slavin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The International Center for Cell Therapy &amp; Cancer Immunotherapy (CTCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The International Center for Cell Therapy &amp; Cancer Immunotherapy (CTCI)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Shimon Slavin MD</name_title>
    <organization>The International Center for Cell Therapy &amp; Cancer Immunotherapy (CTCI)</organization>
  </responsible_party>
  <keyword>Tumor cell vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

